The Technology Maturation Fund, a program managed by the Clemson University Research Foundation (CURF), is unlike any other source of funding available to Clemson faculty. The purpose of this funding is solely to support the last critical step that will significantly increase the likelihood of commercialization of Clemson intellectual property. Click on Technology Maturation Fund May 2014 for more information.
KIYATEC Inc. has appointed Bob Silverman as Board Chairman of the company. Mr. Silverman has been a member of the company’s Board of Directors since 2012. Click here to read the full press release.
Clemson University’s Call Me MISTER program has received $1.3 million from the W.K. Kellogg Foundation (WKKF) of Battle Creek, Michigan, to collaborate with Jackson State University (JSU) to increase the number of African-American male teachers in Mississippi K-8 classrooms. Read more here.
A Clemson University team made up of bioengineering and business administration students were named finalists in a challenge to accelerate commercialization and spur entrepreneurship. The team created a business plan for an invention that provides a new approach to tissue regeneration following breast cancer surgery that may one day change the way doctors treat the disease. Read the full story here.
CLEMSON — Inventors, entrepreneurs and industry representatives gathered Tuesday at the Madren Conference Center for a university and industry networking reception honoring Clemson University’s top inventors and 2012 patent recipients.
Hosted by the Clemson University Research Foundation (CURF) and the Clemson Inventor’s Club, the event recognized researchers whose contributions in biomedical devices, biotechnology (sustainable environment), semiconductors and health generated 15 U.S. patents in calendar year 2012. They added to the current Clemson patent catalog of 168 active U.S. and foreign patents available for licensing and commercialization.
In addition to the patent recognition, the event featured a presentation by Anthony Boccanfuso, executive director of the National Academies’ University-Industry Demonstration Partnership, titled “A perspective on the University/Industry Collaborative Research Model.”
Formed in November 2012, the Clemson Inventor’s Club recognizes Clemson’s most active inventors and faculty entrepreneurs across colleges and disciplines and provides opportunities for them to connect and share ideas with each other and others in the intellectual property and commercialization sectors and introduce Clemson discoveries to the marketplace.
Discussion topics included entrepreneurship, invention and intellectual property, sponsored research, small business research funding opportunities and pure and simple networking to continue to foster the culture of innovation that already exists at Clemson.
“Feedback from past club events indicate that the faculty are as interested in meeting each other and learning about the innovative research going on in their own backyard as they are in meeting others from the business community,” said Casey Porto, executive director of the Research Foundation. “The club structure is really meant to be organic – just bring the innovators together with community business mentors and investors, step back and see what happens.”
New this year, CURF has created a talented Tech Analyst team by tapping into Clemson Graduate students and the engineering co-op program. The analysts have proven technical skills combined with interest in helping CURF identify and protect promising technologies and move them to commercial sector. Click here to read more.
Contract awarded under the Small Business Innovative Research (“SBIR”) Program to establish patient-derived, 3D micro‐tumors designed to be used to screen anticancer drugs during development and to test patient‐derived samples in real time to assist clinical decision making
GREENVILLE, South Carolina, Oct 24, 2013 ‐‐ KIYATEC Inc. (www.kiyatec.com) today announced that the National Cancer Institute (NCI), one of the 27 institutes and centers that comprise the National Institutes of Health (NIH), awarded the company an approximately $295,000 Phase I SBIR (Small Business Innovation Research) contract to establish 3D breast cancer models using living cells obtained directly from breast cancer patients. Accurate modeling of the response of a patient’s cancer to a drug will help them in two ways – to reduce failures of anticancer drugs during clinical trials because of earlier, more relevant information on drug effectiveness, and to test patient‐derived samples in real time for clinical decision making specific to that individual.
INC., April 18, 2013
Special Report: The 25 Most Audacious Companies
Eric Markowitz | Inc.com staff
Kidneys, livers, whatever, made to order in a lab. With Organovo’s 3-D printing technology, it’s possible.
Right now in the United States, nearly 120,000 people are waiting for an organ transplant. Among them, 95,000 are waiting for a kidney, 15,000 need a liver, and 3,000 must get a heart. Depending on age, blood type, and ethnicity, these patients will wait anywhere from a few months to a few years for an organ–and some won’t get it in time.
Keith Murphy, CEO of the biomedical engineering start-up Organovo, thinks there’s a better answer: 3-D bioprinting. Doctors could create an organ in a lab precisely when it’s needed.
“Surgeons are very limited by what they have available today,” Murphy says. “If you can give them tissue to order, you can multiply, exponentially, the types of surgery that we can even envision doing. And if you could do it with a patient’s own cells, surgeons could go places they haven’t gone before.”
They’re printing what?
Professor Gabor Forgacs and his team at the University of Missouri, Columbia, developed Organovo’s technology and founded the company in 2007. Since then, Organovo has made startling progress in the tissue engineering field. Unlike other tissue engineering methods, which make use of polymers–biomaterials that create structure and bond to cells–Organovo’s NovoGen MMX Bioprinter uses human cells and shapes them into real tissue.
It may sound like science fiction, but it’s all possible through a carefully controlled engineering feat.
As with any 3-D printer, lasers guide the production of each tissue. But instead of ink or plastic molding, the printer ejects a liquid filled with thousands of human cells. The process repeats, creating multiple “stacks” of cell layers, and a noninvasive gel holds the stacks together.
Then, cell biology kicks in: The cells assemble themselves as they would in a developing human body and mature, finally, into actual tissue.
Race to market
To be sure, Organovo isn’t the only team working on 3-D bioprinting and tissue engineering. Academic institutions around the country, including Columbia, Cornell, and Wake Forest, have scores of researchers devoted to this very concept. But experts in the field point to Organovo’s progress.
“These kinds of surgical tools have been lacking for a long time,” says Dr. G. Sitta Sittampalam, a senior adviser and project manager at the National Institutes of Health and an expert in cell pharmacology and 3-D tissues. “This is very important.”
To date, Organovo has used the technology to conduct research on liver cells and collaborated with both private enterprises and academic institutions (Pfizer and Harvard Medical School, for instance) to test tissue samples. In 2012, the company received multiple patents.
The biggest challenge in tissue engineering is thickness: Ultimately, Murphy says, going from tissues that are 1 millimeter thick to 5 millimeters thick will be harder than going from 5-millimeter tissue to building an organ. “We’re still a couple years off,” Murphy says, “but we’re moving forward.”
Clemson University College of Engineering and Science I-Corps teams took the top two spots in a presentation competition in Atlanta. The National Science Foundation Innovation Corps (I-Corps) program fosters entrepreneurship that could lead to the commercialization of technology that has been supported by NSF-funded research. Read the entire release here: http://www.clemson.edu/media-relations/4507
3D printing is an expanding technology in the biomedical industry, and Clemson researchers have played a role in its advancement. This technology enables scientists to utilize an inkjet printer to print tissues such as blood vessels, knee cartilage, and bone implants, to name a few. Read the whole story here.
Clemson professors Eric Muth and Adam Hoover created a device that may help people re-think their food choices, and how much of it they’re willing to consume.